Mecasermin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Mecasermin
Clinical data
AHFS/Drugs.com monograph
Pregnancy cat. C (US)
Legal status -only (US)
Routes Subcutaneous
Identifiers
CAS number 68562-41-4 N
ATC code H01AC03
DrugBank DB01277
UNII 7GR9I2683O YesY
KEGG D04870 N
ChEMBL CHEMBL1201716 N
Chemical data
Formula C331H512N94O101S7 
Mol. mass 7648.67 g/mol
 N (what is this?)  (verify)

Mecasermin (INN, trade name Increlex) is recombinant human insulin-like growth factor 1 (IGF-I), which is used for the long-term treatment of growth failure in children with severe primary IGF-I deficiency.[1][2]

This drug is not to be confused with mecasermin rinfabate (trade name Iplex), which is a combination of recombinant human IGF-1 (rhIGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3). IGFBP-3 serves to prolong the action of IGF-1 in the human body.

References[edit]

  1. ^ Fintini, D; Brufani, C; Cappa, M (2009). "Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency". Therapeutics and clinical risk management 5 (3): 553–9. PMC 2724186. PMID 19707272. 
  2. ^ "Increlex". Drugs.com. Retrieved 10 January 2010.